Shima Y - Search Results

1

CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.

Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, Honma D, Adachi N, Araki K, Kato A, Inaki K, Ono Y, Fukuhara S, Kobayashi Y, Tobinai K, Kitabayashi I. Kagiyama Y, et al. Among authors: shima y. Cancer Sci. 2021 Jun;112(6):2314-2324. doi: 10.1111/cas.14905. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33792119 Free PMC article.

2

Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.

Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I. Li XL, et al. Among authors: shima y. Oncogene. 2007 Nov 8;26(51):7231-9. doi: 10.1038/sj.onc.1210523. Epub 2007 May 28. Oncogene. 2007. PMID: 17533375

3

PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.

Shima Y, Shima T, Chiba T, Irimura T, Pandolfi PP, Kitabayashi I. Shima Y, et al. Among authors: shima t. Mol Cell Biol. 2008 Dec;28(23):7126-38. doi: 10.1128/MCB.00897-08. Epub 2008 Sep 22. Mol Cell Biol. 2008. PMID: 18809579 Free PMC article.

4

Deregulated transcription factors in leukemia.

Shima Y, Kitabayashi I. Shima Y, et al. Int J Hematol. 2011 Aug;94(2):134-141. doi: 10.1007/s12185-011-0905-9. Epub 2011 Aug 9. Int J Hematol. 2011. PMID: 21823042 Review.

5

PML-RARα and its phosphorylation regulate pml oligomerization and HIPK2 stability.

Shima Y, Honma Y, Kitabayashi I. Shima Y, et al. Cancer Res. 2013 Jul 15;73(14):4278-88. doi: 10.1158/0008-5472.CAN-12-3814. Epub 2013 May 30. Cancer Res. 2013. PMID: 23722549

6

Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.

Aikawa Y, Yamagata K, Katsumoto T, Shima Y, Shino M, Stanley ER, Cleary ML, Akashi K, Tenen DG, Kitabayashi I. Aikawa Y, et al. Among authors: shima y. Cancer Sci. 2015 Mar;106(3):227-36. doi: 10.1111/cas.12593. Epub 2015 Feb 12. Cancer Sci. 2015. PMID: 25529853 Free PMC article.

7

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.

Ogawara Y, Katsumoto T, Aikawa Y, Shima Y, Kagiyama Y, Soga T, Matsunaga H, Seki T, Araki K, Kitabayashi I. Ogawara Y, et al. Among authors: shima y. Cancer Res. 2015 May 15;75(10):2005-16. doi: 10.1158/0008-5472.CAN-14-2200. Epub 2015 Mar 20. Cancer Res. 2015. PMID: 25795706

8

MLL is essential for NUP98-HOXA9-induced leukemia.

Shima Y, Yumoto M, Katsumoto T, Kitabayashi I. Shima Y, et al. Leukemia. 2017 Oct;31(10):2200-2210. doi: 10.1038/leu.2017.62. Epub 2017 Feb 17. Leukemia. 2017. PMID: 28210005

9

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I. Machida Y, et al. Among authors: shima y. Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727689

10

Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.

Ito J, Yamagata K, Shinohara H, Shima Y, Katsumoto T, Aikawa Y, Kitabayashi I. Ito J, et al. Among authors: shima y. Int J Hematol. 2023 Jan;117(1):78-89. doi: 10.1007/s12185-022-03469-8. Epub 2022 Oct 24. Int J Hematol. 2023. PMID: 36280659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

810 results

Search Page

Filters